Understanding how IRF4 affects the tumor environment in follicular lymphoma
Official title: Elucidating the role of IRF4 in reprogramming the tumor microenvironment in follicular lymphoma
Funded at Mayo Clinic Rochester · NIH-10806442 · Data updated 2026-11-12
This study is looking at how a protein called IRF4 affects the environment around tumors in people with follicular lymphoma, a type of blood cancer, to find new ways to improve treatment and help patients feel better.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $178,069 |
| NIH project number | 1K08CA279652-01A1 |
| Project ID | NIH-10806442 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with follicular lymphoma, particularly those experiencing early relapse or poor prognosis.
✕Less likely to help
Patients with other types of lymphoma or those who are not diagnosed with follicular lymphoma may not benefit from this research.
What this research studies
This research investigates the role of a protein called IRF4 in shaping the tumor microenvironment of follicular lymphoma, a type of blood cancer. By analyzing genetic and transcriptomic data, the study aims to uncover how IRF4 influences interactions between cancerous B cells and immune cells, which could lead to poor patient outcomes. The researchers will conduct experiments to explore how increased IRF4 expression alters immune responses and contributes to an immunosuppressive environment. This work seeks to identify potential therapeutic targets that could improve treatment strategies for patients with follicular lymphoma.
Why it matters
Potential benefit: If successful, this research could lead to new treatment approaches that enhance immune responses against follicular lymphoma.
How similar studies have gone: Previous research has shown promising results in understanding tumor-immune interactions in other cancers, suggesting that this approach may yield valuable insights for follicular lymphoma as well.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Mondello, Patrizia — Mayo Clinic Rochester
- Study coordinator: Mondello, Patrizia
Related research
Other NIH-funded projects on the same topics.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Follicular Lymphoma: Better Diagnosis and Personalized Risk in B-Cell Lymphomas
This NIH grant aims to improve how doctors diagnose and predict outcomes for people with follicular lymphoma by finding reliable biomarkers to guide treatment decisions.
-
IRF4's role in shaping the tumor environment in follicular lymphoma
This grant aims to understand how a molecule called IRF4 changes the tumor surroundings in follicular lymphoma to identify potential new ways to help patients.
-
Gene test to predict early treatment failure in follicular lymphoma
A lab test that reads genes in lymphoma biopsy tissue to spot people with follicular lymphoma who are likely to have their disease return within two years after standard immunochemotherapy.
-
How mutant STAT6 affects follicular lymphoma
This project looks at how a gene change called STAT6 affects follicular lymphoma to help find better treatments for people with this cancer.
-
Preventing the progression of follicular lymphoma with targeted therapy
This study is looking at how slow-growing follicular lymphomas can change into more aggressive forms, and it's working to find personalized treatments that target the specific factors that help these tumors survive, so we can help patients live better and longer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.